AR065277A1 - Combinaciones de benzotiazolona agonista 2-beta-adrenoceptor - Google Patents
Combinaciones de benzotiazolona agonista 2-beta-adrenoceptorInfo
- Publication number
- AR065277A1 AR065277A1 ARP080100560A ARP080100560A AR065277A1 AR 065277 A1 AR065277 A1 AR 065277A1 AR P080100560 A ARP080100560 A AR P080100560A AR P080100560 A ARP080100560 A AR P080100560A AR 065277 A1 AR065277 A1 AR 065277A1
- Authority
- AR
- Argentina
- Prior art keywords
- antagonist
- inhibitor
- bromide
- azoniabicyclo
- octane
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 abstract 2
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 abstract 1
- -1 2 - {[2- (4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazole- 7-yl) ethyl] amino} ethyl Chemical group 0.000 abstract 1
- HVTUHSABWJPWNK-UHFFFAOYSA-N 2-[2-chloro-5-[3-(5-chlorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-(methylcarbamoyl)phenoxy]-2-methylpropanoic acid Chemical compound CNC(=O)C1=CC(Cl)=C(OC(C)(C)C(O)=O)C=C1OCC(O)CN1CCC2(OC3=CC=C(Cl)C=C3C2)CC1 HVTUHSABWJPWNK-UHFFFAOYSA-N 0.000 abstract 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 abstract 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 abstract 1
- 229940124638 COX inhibitor Drugs 0.000 abstract 1
- 229940124003 CRTH2 antagonist Drugs 0.000 abstract 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 abstract 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 abstract 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- 229940122296 IKK2 inhibitor Drugs 0.000 abstract 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 abstract 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 229940122159 Myeloperoxidase inhibitor Drugs 0.000 abstract 1
- 101100532722 Ovis aries SCNN1B gene Proteins 0.000 abstract 1
- 239000012826 P38 inhibitor Substances 0.000 abstract 1
- 229940126033 PPAR agonist Drugs 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- RUJOTWZWKJZHDL-WHWSVKSPSA-N [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] (2s)-2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate Chemical compound C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CCOC=3C=CC=CC=3)C2)C=2SC=CC=2)CCCC1 RUJOTWZWKJZHDL-WHWSVKSPSA-N 0.000 abstract 1
- APHZOQIAYNXYFH-UHFFFAOYSA-M [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-2-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide Chemical compound [Br-].C=1C=CSC=1C(C=1SC=CC=1)(O)C(=O)OC1CC(CC2)CC[N+]12CCCOC1=CC=CC=C1 APHZOQIAYNXYFH-UHFFFAOYSA-M 0.000 abstract 1
- 229960005012 aclidinium bromide Drugs 0.000 abstract 1
- XLAKJQPTOJHYDR-QTQXQZBYSA-M aclidinium bromide Chemical group [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 XLAKJQPTOJHYDR-QTQXQZBYSA-M 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000002559 chemokine receptor antagonist Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229940015042 glycopyrrolate Drugs 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 229960001609 oxitropium bromide Drugs 0.000 abstract 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 229960004633 pirenzepine Drugs 0.000 abstract 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 101150082646 scnn1a gene Proteins 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 229950004351 telenzepine Drugs 0.000 abstract 1
- 239000002396 thromboxane receptor blocking agent Substances 0.000 abstract 1
- 229960000257 tiotropium bromide Drugs 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Producto farmacéutico que comprende un primer ingrediente activo que es N-[2-dietilamino)etil]-N-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(naftil)etoxi]propanamida o una sal de la misma, y un segundo ingrediente activo seleccionado entre: un agonista de un receptor de glucocorticoides no esteroides (receptor GR); un antioxidante; un antagonista de CCR1; un antagonista de quimioquina (no CCR1); un corticosteroide; un antagonista de CRTh2; un antagonista de DP1; un inductor de la histona desacetilasa; un inhibidor de IKK2; un inhibidor de COX; un inhibidor de lipoxigenasa; un antagonista del receptor de leucotrieno; un inhibidor de MPO; un antagonista muscarínico que es bromuro de aclidinio. Glicopirrolato, bromuro de oxitropio, pirenzepina, telenzepina, bromuro de tiotropio, bromuro de 3(R)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo[2.2.2]octano, bromuro de 3(R)-1-fenetil-3-(9H-xanten-9-carboniloxi)-1- azoniabiciclo[2.2.2]octano o bromuro de 3(R)-3-[(2S)-2-ciclopentil-2-hidroxi-2-tien-2-ilacetoxi]-1-(2-fenoxietil)-1-azoniabiciclo[2.2.2]octano, un inhibidor de p38; un inhibidor de PDE; un agonista de PPAR; un inhibidor de proteasa; una estatina; un antagonista de tromboxano; un vasodilatador; o un bloqueante de ENAC (bloqueante de los canales de sodio epiteliales); y su uso en el tratamiento de enfermedades respiratorias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0702456.5A GB0702456D0 (en) | 2007-02-08 | 2007-02-08 | New combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065277A1 true AR065277A1 (es) | 2009-05-27 |
Family
ID=37898976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100560A AR065277A1 (es) | 2007-02-08 | 2008-02-08 | Combinaciones de benzotiazolona agonista 2-beta-adrenoceptor |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20100029732A1 (es) |
| EP (2) | EP2117542B1 (es) |
| JP (1) | JP2010518056A (es) |
| KR (1) | KR20090114391A (es) |
| CN (1) | CN101652137A (es) |
| AR (1) | AR065277A1 (es) |
| AT (1) | ATE520401T1 (es) |
| AU (1) | AU2008212713A1 (es) |
| BR (1) | BRPI0806964A2 (es) |
| CA (1) | CA2675465A1 (es) |
| CL (1) | CL2008000379A1 (es) |
| CO (1) | CO6210723A2 (es) |
| CY (1) | CY1111932T1 (es) |
| DK (1) | DK2117542T3 (es) |
| EC (1) | ECSP099567A (es) |
| ES (1) | ES2368967T3 (es) |
| GB (1) | GB0702456D0 (es) |
| HR (1) | HRP20110695T1 (es) |
| IL (1) | IL199840A0 (es) |
| MX (1) | MX2009007865A (es) |
| PE (1) | PE20081759A1 (es) |
| PL (1) | PL2117542T3 (es) |
| PT (1) | PT2117542E (es) |
| RS (1) | RS51956B (es) |
| RU (1) | RU2009133255A (es) |
| SI (1) | SI2117542T1 (es) |
| TW (1) | TW200843750A (es) |
| UY (1) | UY30906A1 (es) |
| WO (1) | WO2008096111A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| BRPI0822693A2 (pt) | 2008-05-13 | 2015-07-07 | Astrazeneca Ab | Derivados de quinuclidina como antagonistas do receptor muscarínico m3 |
| BRPI0912657A2 (pt) * | 2008-05-13 | 2016-01-26 | Astrazeneca Ab | produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor |
| EP2303873A4 (en) | 2008-06-18 | 2012-01-04 | Astrazeneca Ab | BENZOXAZINE DERIVATIVES AS A BETA2 ADRENORE RECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISEASES |
| CN102131505A (zh) * | 2008-06-20 | 2011-07-20 | 阿斯利康(瑞典)有限公司 | 用于调节β2-肾上腺素受体活性的包含4-羟基-2-氧代-2，3-二氢-1，3-苯并噻唑-7-基化合物的药物组合物 |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| US9827212B2 (en) | 2009-03-18 | 2017-11-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating asthma and other lung diseases |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| HUE044653T2 (hu) | 2009-07-22 | 2019-11-28 | PureTech Health LLC | Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| WO2016038116A1 (en) | 2014-09-09 | 2016-03-17 | Vectura Limited | Formulation comprising glycopyrrolate, method and apparatus |
| EA032221B1 (ru) * | 2015-05-04 | 2019-04-30 | Астразенека Аб | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) |
| CA3180743A1 (en) | 2018-09-28 | 2020-04-02 | Karuna Therapeutics, Inc. | Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE378109B (es) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0104251D0 (sv) | 2001-12-14 | 2001-12-14 | Astrazeneca Ab | Novel compounds |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| GB0402797D0 (en) * | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| CA2583428A1 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| AU2005300150A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| US20090012051A1 (en) | 2005-03-15 | 2009-01-08 | Kyowa Hakko Kogyo Co., Ltd. | External preparation |
| TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200821316A (en) | 2006-07-19 | 2008-05-16 | Astrazeneca Ab | Novel compounds 243 |
-
2007
- 2007-02-08 GB GBGB0702456.5A patent/GB0702456D0/en not_active Ceased
-
2008
- 2008-02-04 TW TW097104221A patent/TW200843750A/zh unknown
- 2008-02-06 RU RU2009133255/15A patent/RU2009133255A/ru not_active Application Discontinuation
- 2008-02-06 DK DK08702047.5T patent/DK2117542T3/da active
- 2008-02-06 EP EP08702047A patent/EP2117542B1/en active Active
- 2008-02-06 JP JP2009548730A patent/JP2010518056A/ja not_active Withdrawn
- 2008-02-06 AT AT08702047T patent/ATE520401T1/de active
- 2008-02-06 AU AU2008212713A patent/AU2008212713A1/en not_active Abandoned
- 2008-02-06 SI SI200830397T patent/SI2117542T1/sl unknown
- 2008-02-06 PL PL08702047T patent/PL2117542T3/pl unknown
- 2008-02-06 KR KR1020097016587A patent/KR20090114391A/ko not_active Application Discontinuation
- 2008-02-06 ES ES08702047T patent/ES2368967T3/es active Active
- 2008-02-06 BR BRPI0806964-6A2A patent/BRPI0806964A2/pt not_active IP Right Cessation
- 2008-02-06 CA CA002675465A patent/CA2675465A1/en not_active Abandoned
- 2008-02-06 RS RS20110435A patent/RS51956B/en unknown
- 2008-02-06 WO PCT/GB2008/000386 patent/WO2008096111A1/en active Application Filing
- 2008-02-06 PT PT08702047T patent/PT2117542E/pt unknown
- 2008-02-06 CN CN200880010926A patent/CN101652137A/zh active Pending
- 2008-02-06 MX MX2009007865A patent/MX2009007865A/es not_active Application Discontinuation
- 2008-02-06 EP EP11163020A patent/EP2364704A1/en not_active Withdrawn
- 2008-02-06 US US12/526,328 patent/US20100029732A1/en not_active Abandoned
- 2008-02-06 CL CL200800379A patent/CL2008000379A1/es unknown
- 2008-02-07 US US12/027,424 patent/US20080242649A1/en not_active Abandoned
- 2008-02-07 PE PE2008000269A patent/PE20081759A1/es not_active Application Discontinuation
- 2008-02-08 AR ARP080100560A patent/AR065277A1/es not_active Application Discontinuation
- 2008-02-08 UY UY30906A patent/UY30906A1/es unknown
-
2009
- 2009-07-13 IL IL199840A patent/IL199840A0/en unknown
- 2009-07-21 CO CO09075448A patent/CO6210723A2/es not_active Application Discontinuation
- 2009-08-06 EC EC2009009567A patent/ECSP099567A/es unknown
-
2011
- 2011-09-28 HR HR20110695T patent/HRP20110695T1/hr unknown
- 2011-10-12 CY CY20111100976T patent/CY1111932T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080242649A1 (en) | 2008-10-02 |
| BRPI0806964A2 (pt) | 2014-04-08 |
| CO6210723A2 (es) | 2010-10-20 |
| JP2010518056A (ja) | 2010-05-27 |
| RS51956B (en) | 2012-02-29 |
| ATE520401T1 (de) | 2011-09-15 |
| AU2008212713A1 (en) | 2008-08-14 |
| MX2009007865A (es) | 2009-07-31 |
| ECSP099567A (es) | 2009-09-29 |
| KR20090114391A (ko) | 2009-11-03 |
| PL2117542T3 (pl) | 2011-12-30 |
| EP2117542B1 (en) | 2011-08-17 |
| CL2008000379A1 (es) | 2008-10-24 |
| RU2009133255A (ru) | 2011-03-20 |
| EP2364704A1 (en) | 2011-09-14 |
| PT2117542E (pt) | 2011-10-06 |
| UY30906A1 (es) | 2008-09-30 |
| CA2675465A1 (en) | 2008-08-14 |
| HRP20110695T1 (hr) | 2011-11-30 |
| DK2117542T3 (da) | 2011-10-31 |
| WO2008096111A1 (en) | 2008-08-14 |
| GB0702456D0 (en) | 2007-03-21 |
| IL199840A0 (en) | 2010-04-15 |
| CY1111932T1 (el) | 2015-11-04 |
| PE20081759A1 (es) | 2009-01-31 |
| US20100029732A1 (en) | 2010-02-04 |
| TW200843750A (en) | 2008-11-16 |
| CN101652137A (zh) | 2010-02-17 |
| ES2368967T3 (es) | 2011-11-24 |
| SI2117542T1 (sl) | 2011-11-30 |
| EP2117542A1 (en) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065277A1 (es) | Combinaciones de benzotiazolona agonista 2-beta-adrenoceptor | |
| WO2009037503A3 (en) | New combination - 012 for the treatment of respiratory diseases | |
| AR072262A1 (es) | COMBINACION -408, QUE COMPRENDE N-CICLOHEXIL-N3-[2-(3-FLUOROFENIL)ETIL]-N-(2-{[2-(4-HIDROXI-2-OXO-2,3-DIHIDRO-1,3-BENZOTIAZOL-7-IL)ETIL]AMINO}ETIL- beta-ALANINAMIDA.USO. METODO. CONJUNTO DE ELEMENTOS. COMPOSICION FARMACEUTICA. INTERMEDIARIO. | |
| GB201021992D0 (en) | Compound | |
| NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
| NO20066016L (no) | Diamin beta2 adrenergiske receptoragonister | |
| GB201021979D0 (en) | New compound | |
| AR054445A1 (es) | Formulaciones de un inhibidor de src/abl | |
| PE20130215A1 (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta2 y como antagonistas muscarinicos m3 | |
| ES2422557T3 (es) | Compuestos y composiciones como moduladores de la ruta Hedgehog | |
| ES2421613T3 (es) | Composición farmacéutica externa | |
| GEP20115357B (en) | Amine derivatives | |
| EA200500146A1 (ru) | Моноэтансульфонат 3-z-[1-4-(n-((4-метилпиперазин-1-ил)метилкарбонил)-n-метиламино)анилино)-1-фенилметилен]-6-метоксикарбонил-2-индолинона и его применение в составе фармацевтической композиции | |
| ATE478072T1 (de) | Spiroimidazol-derivate als ppar-modulatoren | |
| EA200801369A1 (ru) | Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа | |
| Trabbic et al. | Synthesis and biological evaluation of indolyl-pyridinyl-propenones having either methuosis or microtubule disruption activity | |
| NZ587929A (en) | Chemokine receptor modulators | |
| AR053169A1 (es) | Metabolitos de n-2 (cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil) -2-metil -4-pi rimidinil] amino]-5-tiazol carboxamidas | |
| ATE444066T1 (de) | Liganden für den cannabinoidrezeptoren | |
| CL2008001297A1 (es) | N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer. | |
| EA200970303A1 (ru) | Тиазолпиразолопиримидин в качестве антагониста рецептора крф1 | |
| PE20121084A1 (es) | Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 | |
| UY29181A1 (es) | Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones | |
| PE20070069A1 (es) | Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a | |
| ES2531335T3 (es) | Derivados de 5-aminoindol 4,6-disubstituido y de 5-aminoindolina 4,6-disubstituida como moduladores de los canales de potasio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |